SCHEMBL6433898

SCHEMBL6433898

O=C(O)C(=O)c1c[nH]c2c(O)ccnc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 2/20 0.45
KDM5A P29375 1/20 0.45
TET2 Q6N021 2/20 0.39
TET1 Q8NFU7 2/20 0.39
KDM4E B2RXH2 5/20 0.37
L3MBTL1 Q9Y468 4/20 0.37
KDM4A O75164 2/20 0.37
EGLN1 Q9GZT9 2/20 0.37
RAB9A P51151 1/20 0.37
HIF1AN Q9NWT6 1/20 0.37
KDM6B O15054 1/20 0.34
KDM6A O15550 1/20 0.34
TET3 O43151 1/20 0.34
KDM4B O94953 1/20 0.34
KDM5C P41229 1/20 0.34
KDM4D Q6B0I6 1/20 0.34
ALKBH5 Q6P6C2 1/20 0.34
FTO Q9C0B1 1/20 0.34
KDM2A Q9Y2K7 1/20 0.34
KDM3A Q9Y4C1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1472608 0.84 KDM5A (0.56) KDM4CKDM5ATET2TET1KDM4E
SCHEMBL12238753 0.83 KDM5A (0.44) KDM4CKDM5ATET2TET1RAB9A
SCHEMBL7063133 0.82 KDM5A (0.38) KDM4CKDM5ATET2TET1KDM4E
SCHEMBL2628954 0.73 KDM5A (0.38) KDM4CKDM5ATET2TET1KDM4E
SCHEMBL3202808 0.73 CYP3A4 (0.47) KDM4CKDM5AKDM4EL3MBTL1ALDH1A1
SCHEMBL6432355 0.72 CYP2C19 (0.49) KDM4CTET2TET1KDM4EL3MBTL1
Potassium SCHEMBL1763544 0.72 KDM5A (0.37) KDM4CKDM5ATET2TET1RAB9A
SCHEMBL1763541 0.72 KDM5A (0.37) KDM4CKDM5ATET2TET1RAB9A
SCHEMBL6733348 0.70 KDM4C (0.69) KDM4CKDM5ATET2TET1KDM4E
SCHEMBL29951570 0.70 CCR1 (0.43) KDM4CKDM5AKDM4EL3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1257276-B1 ANTIVIRAL AZAINDOLE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-12-28 EP disclosed
US-6900323-B2 Antiviral azaindole derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-31 US disclosed
EP-1257276-A4 ANTIVIRAL AZAINDOLE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2004-10-27 EP disclosed
US-20040023982-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2004-02-05 US disclosed
US-6632819-B1 HIV and AIDS BRISTOL-MYERS SQUIBB COMPANY 2003-10-14 US disclosed
EP-1257276-A1 ANTIVIRAL AZAINDOLE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-11-20 EP disclosed
US-6476034-B2 AIDS THERAPY BRISTOL-MYERS SQUIBB COMPANY 2002-11-05 US disclosed
US-20020119982-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-08-29 US disclosed
US-20020061892-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-05-23 US disclosed
WO-2001062255-A1 ANTIVIRAL AZAINDOLE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119982-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 KDM4C 734/4885KDM5A 288/4885TET2 341/4885
US-20020061892-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 KDM4C 734/4885KDM5A 288/4885TET2 341/4885
US-20040023982-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, EIF2AK2 KDM4C 863/4885KDM5A 399/4885TET2 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.